Potential risks related to anabolic steroids use on nervous, cardiovascular and reproductive systems disorders in men

1. Austad SN. Why women live longer than men: sex differences in longevity. Gend Med. 2006;3(2):79-92.10.1016/S1550-8579(06)80198-1Search in Google Scholar

2. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 20041;10(5):409-19.10.1093/humupd/dmh03515297434Search in Google Scholar

3. Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med. 2012;42(2): 119-34.10.2165/11598060-000000000-0000022229259Search in Google Scholar

4. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534-42.10.1177/036354650326220214977687Search in Google Scholar

5. Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21(03):225-7.10.1055/s-2000-30410834358Search in Google Scholar

6. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. 2008;29(2):182-98.10.1016/j.yfrne.2007.08.00417983646Search in Google Scholar

7. Vicencio JM, Estrada M, Galvis D, Bravo R, E Contreras A, Rotter D, et al. Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications. Mini Rev Med Chem. 2011;11(5):390-8.10.2174/138955711795445880441621121443511Search in Google Scholar

8. Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res. 2013;19(13):3353-9.10.1158/1078-0432.CCR-12-0931373609523470964Search in Google Scholar

9. Siemińska L. Tkanka tłuszczowa. Patofizjologia, rozmieszczenie, różnice płciowe oraz znaczenie w procesach zapalnych i nowotworowych. Endokrynol Pol. 2007;58(4):330-49.Search in Google Scholar

10. Neves MA, Dinis TC, Colombo G, Sá e Melo ML. Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem. 2007;2(12):1750-62.10.1002/cmdc.20070014917910019Search in Google Scholar

11. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Natural products as aromatase inhibitors. Anticancer Agents Med Chem. 2008;8(6):646-82.10.2174/187152008785133092Search in Google Scholar

12. Bosco C, Colli R, Bonomi R, Von Duvillard SP, Viru A. Monitoring strength training: neuromuscular and hormonal profile. Med Sci Sports Exerc. 2000;32(1):202-8.10.1097/00005768-200001000-0003010647550Search in Google Scholar

13. Powers ME. The safety and efficacy of anabolic steroid precursors: what is the scientific evidence? J Athl Train. 2002;37(3):300-305.Search in Google Scholar

14. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011;365(24):2255-67.10.1056/NEJMoa110757922085343Search in Google Scholar

15. Nimptsch K, Platz EA, Willett WC, Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf). 2012;77(1):106-12.10.1111/j.1365-2265.2012.04332.x371234822220644Search in Google Scholar

16. Chmiel-Majewska K, Daniewska D, Misiorowski G, Zgliczyński W, Gellert R. Vitamin D, sex hormones and anaemia in men–is there an influence of cholecalciferol supplementation on haemoglobin concentrations or regulation of sex hormones in male haemodialysis patients? A pilot study. Post Nauk Med. 2015;10:688-92.10.5604/08606196.1189835Search in Google Scholar

17. Staton A. Integrative Medicine. Rakel D. Elsevier USA: 2012;321-334.10.1016/B978-1-4377-1793-8.00034-0Search in Google Scholar

18. Hunt CD, Johnson PE, Herbel J, Mullen LK. Effects of dietary zinc depletion on seminal volume and zinc loss, serum testosterone concentrations, and sperm morphology in young men. Am J Clin Nutr. 1992;56(1):148-57.10.1093/ajcn/56.1.1481609752Search in Google Scholar

19. Wang C, Catlin DH, Starcevic B, Heber D, Ambler C, Berman N, et al. Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab. 2005;90(6):3550-9.10.1210/jc.2004-153015741266Search in Google Scholar

20. Steels E, Rao A, Vitetta L. Physiological aspects of male libido enhanced by standardized Trigonella foenum graecum extract and mineral formulation. Phytother Res. 2011;25(9):1294-300.10.1002/ptr.336021312304Search in Google Scholar

21. Shaner AA, Vingren JL, Hatfield DL, Budnar Jr RG, Duplanty AA, Hill DW. The acute hormonal response to free weight and machine weight resistance exercise. J Strength Cond Res. 2014;28(4):1032-40.10.1519/JSC.000000000000031724276305Search in Google Scholar

22. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-61.10.1001/jama.296.19.235117105798Search in Google Scholar

23. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974.10.1176/ajp.153.8.974Search in Google Scholar

24. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003;28(3):317-31.10.1016/S0306-4530(02)00025-2Search in Google Scholar

25. Henderson LP, Penatti CA, Jones BL, Yang P, Clark AS. Anabolic androgenic steroids and forebrain GABAergic transmission. Neuroscience. 2006;138(3):793-9.10.1016/j.neuroscience.2005.08.03916310317Search in Google Scholar

26. Ambar G, Chiavegatto S. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice. Genes Brain Behav. 2009;8(2):161-73.10.1111/j.1601-183X.2008.00458.x19055689Search in Google Scholar

27. Kohtz AS, Frye CA. Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models. Methods Mol Biol. 2012;829:397-431.10.1007/978-1-61779-458-2_2622231829Search in Google Scholar

28. Brower KJ. Anabolic steroid abuse and dependence. Phys Sportsmed. 2002;4(5):377-87.10.1007/s11920-002-0086-612230967Search in Google Scholar

29. Malone JD, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med. 1995;5(1):25-31.10.1097/00042752-199501000-000057614077Search in Google Scholar

30. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901.10.1016/j.amjcard.2010.05.013411156520816133Search in Google Scholar

31. Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17(10):1576-83.10.1093/oxfordjournals.eurheartj.a0147248909917Search in Google Scholar

32. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54.10.2165/00007256-200434080-0000315248788Search in Google Scholar

33. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein 2 cholesterol. Metabolism. 1987;36(10):949-52.10.1016/0026-0495(87)90130-2Search in Google Scholar

34. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses. 1991;35(1):27-31.10.1016/0306-9877(91)90079-ESearch in Google Scholar

35. Nakao J, Chang WC, Murota SI, Orimo H. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981;39(2):203-9.10.1016/0021-9150(81)90070-8Search in Google Scholar

36. Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36(7):483-8.10.1111/j.1365-2362.2006.01667.x16796605Search in Google Scholar

37. Alen M. Androgenic steroid effects on liver and red cells. Br J Sports Med. 1985;19(1):15-20.10.1136/bjsm.19.1.1514782113995222Search in Google Scholar

38. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. 1996;17(12):1912.10.1093/oxfordjournals.eurheartj.a0148128960437Search in Google Scholar

39. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, Van’t Laar A, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med. 1988;9(01):19-23.10.1055/s-2007-10249723366514Search in Google Scholar

40. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004; 90(5):496-501.10.1136/hrt.2003.015719176822515084541Search in Google Scholar

41. Di Bello V, Giorgi D, Bianchi MA, et al. Effects of anabolic-androgenic steroids on weight-lifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc. 1999;31(4):514-521.10.1097/00005768-199904000-0000410211845Search in Google Scholar

42. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med. 1991;12(04):413-8.10.1055/s-2007-10247041917227Search in Google Scholar

43. Friedl KE, Hannan Jr CJ, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39(1):69-74.10.1016/0026-0495(90)90150-BSearch in Google Scholar

44. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med. 2003;24(05):344-51.10.1055/s-2003-4070512868045Search in Google Scholar

45. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98(3):256-61.10.1161/01.CIR.98.3.256Search in Google Scholar

46. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24(3):313-40.10.1210/er.2003-000512788802Search in Google Scholar

47. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90(5):473-5.10.1136/hrt.2003.025783176819715084526Search in Google Scholar

48. El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J. Anabolic steroids abuse and male infertility. Basic Clin Androl. 2016;26(1):2.10.1186/s12610-016-0029-4Search in Google Scholar

49. Pirola I, Cappelli C, Delbarba A, Scalvini T, Agosti B, Assanelli D, et al. Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism. Fertil Steril. 2010;94(6):2331-e1.10.1016/j.fertnstert.2010.03.04220416868Search in Google Scholar

50. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid–induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-9.10.1016/j.fertnstert.2014.02.00224636400Search in Google Scholar

51. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860-5.10.1111/j.1464-410X.2011.10131.x21682835Search in Google Scholar

52. Nangia AK. Anabolic steroid abuse: a paradox of manliness. Fertil Steril. 2014;101(5):1247.10.1016/j.fertnstert.2014.02.03424680369Search in Google Scholar